Safi Biotherapeutics is revolutionizing blood cell therapies by developing on-demand, scalable blood products. As a key partner in a Department of Defense initiative, they focus on addressing the challenges of manufacturing Cell Therapy 2.0. Their expertise lies in expanding blood stem cells and optimizing bioprocesses. Safi’s groundbreaking work includes creating tailored red blood cells for conditions like trauma and sickle cell disease. Led by experienced professionals from biotech and academia, Safi recently secured $5 million in seed funding to accelerate their mission of solving global blood shortages through innovative biomanufacturing solutions.